High Prevalence of Secondary Arterial Hypertension (HIPRESH) with Prospective Systematic Screening in a Cohort of Consecutive Hypertensive Patients Referring to Regional Specialized Center

NCT06664255 | Completed DMC

• 1 other identifier: F 004
• Study Type: observational
• Target: 1,400
• Locations: 0 countries
• Sites: N/A

Brief Summary

Hypertensive Patients referring to our center will undergo a systematic diagnostic workup aimed at finding the cause(s) of their high blood pressure. Information prospective and retrospectively obtained will be analyzed while guaranteeing anonymity.

Conditions

Hypertension; Hypertension Resistant to Conventional Therapy; Secondary Hypertension to Endocrine Disorders; Secondary Hypertension; Secondary Hypertension Renal Arterial

Keywords

Secondary Hypertension; Primary Aldosteronism; Causes; Hyperaldosteronism; Hypertension, Renovascular; Hypertension, Renal; Essential Hypertension; Prevalence

Outcome Measures

Primary Outcomes (1)

• Number of Patients with a Diagnosis of Secondary hypertension

  Conclusive diagnosis of secondary hypertension based on the availble gold standard confirmed by assessment of cure/improvement after target treatment at follow up.

  From enrolment to assessment of cure/target treatment at follow up, an average of 1 year.

Study Arms (1)

Hypertensive patients

Consecutive hypertensive patients referring to our center, and undergoing systematic diagnostic workup for secondary causes of hypertension

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hypertensive patients refering to our center

You may qualify if:

• age ≥18 and \>/= 85 years

You may not qualify if:

• absence of a complete diagnostic work-up due to poor overall clinical conditions or lack of a clear benefit from it
• unwillingness or failure to complete the full diagnostic work-up and/or to attend the outpatient clinic follow-up visits after the first evaluation

Sponsors & Collaborators

• University Hospital Padova: lead

Related Publications (2)

• Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Vehier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G; Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015 May 16;385(9981):1957-65. doi: 10.1016/S0140-6736(14)61942-5. Epub 2015 Jan 26.

  PMID: 25631070 BACKGROUND

• Rossi GP, Bagordo D, Rossi FB, Pintus G, Rossitto G, Seccia TM. 'Essential' arterial hypertension: time for a paradigm change. J Hypertens. 2024 Aug 1;42(8):1298-1304. doi: 10.1097/HJH.0000000000003767. Epub 2024 May 8.

  PMID: 38748508 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood serum samples and 24h urine samples will be obtained by all patients. Further examination will be obtained as required by the diagnostic workup.

MeSH Terms

Conditions

Hypertension; Hypertension Resistant to Conventional Therapy; Hyperaldosteronism; Hypertension, Renovascular; Hypertension, Renal; Essential Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases; Adrenocortical Hyperfunction; Adrenal Gland Diseases; Endocrine System Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Gian Paolo Rossi, MD

  University of Padova

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 22, 2024
• First Posted: October 29, 2024
• Study Start: January 1, 2017
• Primary Completion: January 31, 2023
• Study Completion: January 31, 2023
• Last Updated: October 29, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share